Fig. 3: The anti-cancer properties of SphK2 deficiency in FFA-treated hepatic cells. | Oncogenesis

Fig. 3: The anti-cancer properties of SphK2 deficiency in FFA-treated hepatic cells.

From: Ablation of sphingosine kinase 2 suppresses fatty liver-associated hepatocellular carcinoma via downregulation of ceramide transfer protein

Fig. 3: The anti-cancer properties of SphK2 deficiency in FFA-treated hepatic cells.

Huh7 hepatic cells were transduced with lentiviral-based short hairpin RNA (shRNA) to knock down SphK2 and then treated with a combination of free fatty acids (FFA, 200 µM palmitate + 400 µM oleate). A Cell viability was determined by MTS assay in cells treated with FFA for the indicated times; n = 4. B Colony formation assay was performed over ten days of cell culture in the presence of FFA. The number and size of colonies were quantified; n = 5. C Cell cycle phases were examined in cells treated with FFA for 24 h, using flow cytometry with propidium iodide staining. G0/G1, S, and G2/M phase populations were estimated using FlowJo software and are indicated in blue, yellow and green in histograms, respectively. The percentage of the G2/M phase, indicative of cell cycle progression, was analyzed, n = 5. Data are expressed as mean ± SD. *p < 0.05; ***p < 0.001; versus shCtrl.

Back to article page